Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 19/20 | 0.77 |
| ▸ | MTNR1B | P49286 | 16/20 | 0.77 |
| ▸ | NQO2 | P16083 | 6/20 | 0.70 |
| ▸ | HTR2C | P28335 | 1/20 | 0.70 |
| ▸ | HTR2B | P41595 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8063729 | 0.89 | MTNR1A (0.87) | MTNR1AMTNR1BNQO2HTR2CHTR2B | |
| SCHEMBL15677709 | 0.87 | MTNR1A (0.58) | MTNR1AMTNR1BNQO2HTR2CHTR2B | |
| SCHEMBL7016328 | 0.87 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2HTR2CHTR2B | |
| SCHEMBL30449793 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2HTR2CHTR2B | |
| SCHEMBL4043404 | 0.86 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2HTR2CHTR2B | |
| SCHEMBL4031838 | 0.84 | MTNR1A (0.75) | MTNR1AMTNR1BNQO2HTR2CHTR2B | |
| SCHEMBL3955906 | 0.84 | MTNR1A (0.75) | MTNR1AMTNR1BNQO2HTR2CHTR2B | |
| SCHEMBL5339739 | 0.84 | MTNR1A (0.75) | MTNR1AMTNR1BNQO2HTR2CHTR2B | |
| SCHEMBL5351417 | 0.84 | MTNR1A (0.75) | MTNR1AMTNR1BNQO2HTR2CHTR2B | |
| SCHEMBL27555567 | 0.84 | MTNR1A (0.78) | MTNR1AMTNR1BNQO2HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2533774-B1 | USE OF AGOMELATINE FOR THE PREPARATION OF DRUGS FOR TREATING OBSESSIVE COMPULSIVE DISORDER (OCD) | SERVIER LAB (FR) | 2018-01-31 | — | — | EP | disclosed |
| US-9701608-B2 | Process for the synthesis of 7-methoxy-naphthalene-1-carbaldehyde and application in the synthesis of agomelatine | LES LABORATORIES SERVIER (FR) | 2017-07-11 | — | — | US | disclosed |
| US-9663451-B2 | Forms of co-crystals of agomelatine and p toluenesulphonic acid, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-05-30 | — | — | US | disclosed |
| US-9604911-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2017-03-28 | — | — | US | disclosed |
| US-9527803-B2 | Crystal form VII of agomelatine, preparation method and use thereof and pharmaceutical composition containing same | LES LABORATOIRES SERVIER (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20160368859-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2016-12-22 | — | — | US | disclosed |
| US-20160304429-A1 | PROCESS FOR THE SYNTHESIS OF 7-METHOXY-NAPHTHALENE-1-CARBALDEHYDE AND APPLICATION IN THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2016-10-20 | — | — | US | disclosed |
| US-20160168077-A1 | FORMS OF CO-CRYSTALS OF AGOMELATINE AND p TOLUENESULPHONIC ACID, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-06-16 | — | — | US | disclosed |
| US-20150238614-A1 | STABILISED AMORPHOUS FORM OF AGOMELATINE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | LES LABORATOIRES SERVIER (FR) | 2015-08-27 | — | — | US | disclosed |
| US-8853449-B2 | Process for the synthesis of agomelatine | LES LABORATOIRES SERVIER (FR) | 2014-10-07 | — | — | US | disclosed |
| US-20130289308-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2013-10-31 | — | — | US | disclosed |
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | LES LABORATORIES SERVIER (FR) | 2013-10-10 | — | — | US | disclosed |
| US-8524949-B2 | Agomelatine hydrohalide complex and preparation method thereof | LES LABORATORIES SERVIER (FR) | 2013-09-03 | — | — | US | disclosed |
| US-20130012592-A1 | AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2013-01-10 | — | — | US | disclosed |
| US-20130005820-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2013-01-03 | — | — | US | disclosed |
| US-20120245363-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | LES LABORATOIRES SERVIER (FR) | 2012-09-27 | — | — | US | disclosed |
| WO-2012046253-A2 | PROCESS FOR THE PREPARATION OF N-[2- (7-METHOXY-L-NAPHTHYL) ETHYL] ACETAMIDE AND ITS NOVEL CRYSTALLINE FORMS | MSN LABORATORIES LIMITED (IN) | 2012-04-12 | — | — | WO | disclosed |
| US-20120004313-A1 | CRYSTALLINE FORM VI OF AGOMELATINE, PREPARATION METHOD AND APPLICATION THEREOF | LES LABORATOIRES SERVIER (FR) | 2012-01-05 | — | — | US | disclosed |
| US-20110313198-A1 | AGOMELATINE HYDROHALIDE COMPLEX AND PREPARATION METHOD THEREOF | LES LABORATOIRES SERVIER (FR) | 2011-12-22 | — | — | US | disclosed |
| CN-1135480-A | Alkyl heterocyclic compound and preparation method thereof, and medicinal composition containing that kind of compound | ADIR (FR) | 1996-11-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368859-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | COMT, PNMT, TPH1 | MTNR1A 232/4885MTNR1B 177/4885NQO2 1579/4885 |
| US-20120004313-A1 | CRYSTALLINE FORM VI OF AGOMELATINE, PREPARATION METHOD AND APPLICATION THEREOF | SYMPK, RAB6A, MC3R | MTNR1A 226/4885MTNR1B 102/4885NQO2 4322/4885 |
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | COMT, AGO2, MC5R | MTNR1A 9/4885MTNR1B 11/4885NQO2 3451/4885 |
| US-20120245363-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | COMT, PNMT, TPH1 | MTNR1A 331/4885MTNR1B 293/4885NQO2 1683/4885 |
| US-20160304429-A1 | PROCESS FOR THE SYNTHESIS OF 7-METHOXY-NAPHTHALENE-1-CARBALDEHYDE AND APPLICATION IN THE SYNTHESIS OF AGOMELATINE | COMT, TPH1, TPH2 | MTNR1A 50/4885MTNR1B 67/4885NQO2 947/4885 |
| US-20150238614-A1 | STABILISED AMORPHOUS FORM OF AGOMELATINE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MC4R, ADCYAP1R1, MC3R | MTNR1A 16/4885MTNR1B 19/4885NQO2 4679/4885 |
| US-20110313198-A1 | AGOMELATINE HYDROHALIDE COMPLEX AND PREPARATION METHOD THEREOF | MC2R, MC4R, ADCYAP1R1 | MTNR1A 43/4885MTNR1B 31/4885NQO2 1830/4885 |
| US-20130289308-A1 | PROCESS FOR THE SYNTHESIS OF AGOMELATINE | COMT, PNMT, TPH1 | MTNR1A 331/4885MTNR1B 293/4885NQO2 1683/4885 |
| US-20130005820-A1 | AGOMELATINE HYDROCHLORIDE HYDRATE AND PREPARATION THEREOF | ADCYAP1R1, MC2R, MC4R | MTNR1A 23/4885MTNR1B 27/4885NQO2 2861/4885 |
| US-20130012592-A1 | AGOMELATINE HYDROBROMIDE HYDRATE AND PREPARATION THEREOF | MC2R, MC5R, MC4R | MTNR1A 23/4885MTNR1B 15/4885NQO2 1286/4885 |
| US-20160168077-A1 | FORMS OF CO-CRYSTALS OF AGOMELATINE AND p TOLUENESULPHONIC ACID, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MC5R, COMT, MC3R | MTNR1A 17/4885MTNR1B 27/4885NQO2 4197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.